KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Research & Development (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Research & Development for 16 consecutive years, with $31.9 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 56.04% to $31.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $81.5 million through Dec 2025, up 3.09% year-over-year, with the annual reading at $81.5 million for FY2025, 3.09% up from the prior year.
  • Research & Development for Q4 2025 was $31.9 million at Halozyme Therapeutics, up from $17.3 million in the prior quarter.
  • The five-year high for Research & Development was $31.9 million in Q4 2025, with the low at $8.1 million in Q2 2021.
  • Average Research & Development over 5 years is $17.0 million, with a median of $17.4 million recorded in 2023.
  • The sharpest move saw Research & Development skyrocketed 123.25% in 2022, then dropped 22.56% in 2025.
  • Over 5 years, Research & Development stood at $10.1 million in 2021, then soared by 123.25% to $22.6 million in 2022, then decreased by 5.45% to $21.3 million in 2023, then decreased by 4.19% to $20.4 million in 2024, then skyrocketed by 56.04% to $31.9 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $31.9 million, $17.3 million, and $17.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.